Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026
Written by Micah Zimmerman for The Motley Fool -> Eli Lilly's new oral obesity drug, Foundayo, removes many of the barriers that have limited GLP-1 adoption, potentially expanding the addressable mar
Eli Lilly's new oral obesity drug, Foundayo, removes many of the barriers that have limited GLP-1 adoption, potentially expanding the addressable mark
Read Full Story at Nasdaq News →Why This Matters
The obesity drug market has long been constrained by the dominance of injectable GLP-1 treatments, leaving millions of patients underserved by current options. A shift toward oral medications could unlock a new wave of adoption, potentially reshaping Eli Lilly’s revenue trajectory and the broader pharmaceutical landscape by making anti-obesity therapies more accessible and socially acceptable.
Background Context
Eli Lilly’s experimental oral obesity drug, tirzepatide (Founday), builds on the company’s success with Mounjaro, a diabetes treatment that also demonstrated weight-loss benefits. While oral GLP-1 drugs exist, none have yet matched the efficacy of injectables, creating a critical gap in the market that Founday may finally fill if clinical trials confirm its potential.
What Happens Next
Regulatory approval timelines and trial results will dictate whether Founday can leapfrog competitors like Novo Nordisk’s semaglutide. Investors should monitor phase 3 data, expected in late 2024, for efficacy and safety signals, while keeping an eye on manufacturing scalability—a key factor in determining whether Lilly can meet pent-up demand without supply chain bottlenecks.
Bigger Picture
The obesity drug market is evolving from a niche diabetes-focused segment into a mainstream healthcare priority, with global spending projected to surpass $100 billion annually by 2030. Oral formulations could accelerate this shift by reducing stigma and logistical hurdles, potentially turning Lilly into a household name akin to the early days of Viagra or statins.
